Navigation Links
Highmark Blue Shield and National Association Name Area Hospitals as Blue Distinction Centers for Complex and Rare Cancers
Date:3/11/2008

ng other selection criteria, these hospitals met the following thresholds necessary to be named as Blue Distinction Centers for Complex and Rare Cancers:

-- has multidisciplinary team input, including sub-specialty trained teams

for complex and rare cancers and demonstrated depth of expertise across

cancer disciplines in medicine, surgery, radiation oncology, pathology

and radiology

-- demonstrates ongoing quality management and improvement programs for

cancer care

-- demonstrates an ongoing commitment to using clinical data registries

and providing access to appropriate clinical research for complex and

rare cancers

-- demonstrates sufficient volume of experience in treating rare and

complex cancers

Blue Distinction Centers for Complex and Rare Cancers were developed in strategic collaboration with the National Comprehensive Cancer Network (NCCN) and input from a panel of leading clinicians and professional organizations.

Blue Distinction(R) is a designation awarded by Blue Cross and Blue Shield companies to medical facilities that have demonstrated expertise in delivering quality health care. The designation is based on rigorous, evidence-based selection criteria established in collaboration with leading clinicians, medical societies and professional organizations.

With the current areas, including cardiac care and bariatric surgery already in place, Highmark Blue Shield will have a more comprehensive program focused on quality specialty care compared to other health plans. This designation is for 18 months, and institutions that are a part of the program also are subject to periodic re-evaluation as criteria continue to evolve.

Note: Designation as Blue Distinction Centers means these facilities' overall experience and aggregate data met objective criteria established in collaboration with expert clinicians' and leading medical societies'
'/>"/>

SOURCE Highmark
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Highmark Blue Cross Blue Shield Introduces New Health Plan Comparison Tool for Consumers
2. Highmark Blue Shield Introduces New Health Plan Comparison Tool for Consumers
3. The Highmark Foundation Awards $580,000 in Highmark Healthy High 5 Grants to Four Non-Profit Organizations
4. Highmarks Hospital Pay-for-Performance Program Demonstrates Impressive Results
5. National Magazine Ranks Highmark 62nd Among Nations 500 Most Innovative Users of Information Technology
6. Highmark Medicare Services Awarded New Contract from Centers for Medicare & Medicaid Services
7. Highmark Blue Cross Blue Shield Products Ranked Among Americas Best Health Plans(R)
8. Highmark Blue Cross Blue Shield Program Rewards Members for Enhancing Their Healthstyle
9. Highmark Blue Shield Program Rewards Members for Enhancing their Healthstyle
10. The Highmark Foundation Announces $1 Million School Challenge Program
11. Unique Program Means Better Care for Highmark Members
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2008)... NORWALK, Conn., July 24 /PRNewswire/ -- People t... cruises offer many opportunities to eat right,and...e excellent menu,selections, so if you order caref...u., (Photo: http://www.newscom.com/cgi-bin/prnh/... handle temptation, you,ll want to stay,away from ...
(Date:7/24/2008)... The Palomino Group, a lead...rganization, today announced the launch of its new...o the biopharmaceutical industry. The company, bas...sement and commercialization consulting services t... device, and other healthcare companies. , ...
(Date:7/23/2008)... Press Ganey reports need for better physician-adm...ces of nearly 28,000 physicians, SOUTH BEND, Ind....2008,Hospital Check-Up Report: Physician Perspecti...es to be a gap in the physician-administration,rel...strators to be more,responsive to the ideas and ne...
(Date:7/23/2008)... NASDAQ: CRME, TSX: COM, VANCOUVER, July 23 /PR...Q: CRME/TSX: COM) today announced that it has ente...s, LLC, an investment fund managed by,CR Intrinsic...visors, LLC,to purchase Series A convertible prefe...roceeds of the financing will be used for general ...
Breaking Medicine News(10 mins):Health News:Actress, Author Mariel Hemingway & Travelers Advantage Say: Treat Yourself To a Healthy Cruise 2Health News:Actress, Author Mariel Hemingway & Travelers Advantage Say: Treat Yourself To a Healthy Cruise 3Health News:The Palomino Group Announces Launch of Meeting Support Services Business Unit 2Health News:The Palomino Group Announces Launch of Meeting Support Services Business Unit 3Health News:Authoritative Report on Physician Perspectives Released Today 2Health News:Cardiome Announces Preferred Share Financing 2Health News:Cardiome Announces Preferred Share Financing 3
...ndia has declined over the century from 972 in 190... to 933 in 2001. In contrast, the child sex rati...rls per thousand boys against 945 recorded in 1991...tio is concerned, it is 1.01 male (s)/females as i...
...ntessentially Indian puff, has become a victim of ...outhern districts of Tamil Nadu going on strike. ...wrapped in leaf, from Tirunelveli, Tuticorin and K...this weekend to protest the union health ministry ...
...Democratic Front (LDF) government, set to mark its...at it is to blame for the deaths of 38 newborns in...fection in the labour room of the Sree Avittam Tir...the last two months. A court has charged Health M...
...is of concern as it is a reflection of the prevale...s and the extent of transmission of TB infection ...orted under the programme are of paediatric age gr...ntage of paediatric cases reported at national lev...
Other Medicine News:Health News:Bidi Workers Protest Against Using Skull and Crossbones Sign on Packets 2
(Date:7/22/2008)...rima Exhibits Excellent Drug-Like ...Initiation of Phase II Clinical Trials -, RESEARC...eRx BioPharma,Inc., a clinical stage company deve...or diseases of the central nervous system, today a...a(TM) into Phase II trials for the,treatment of de...
(Date:7/22/2008)...University Medical Center Based on Roset...e Test Differentiates Squamous From Non-Squamous N...uamous-Cell Carcinoma of the Lung With Sens...t,This is the First CLIA Approved Test Which Lever... for Accurate Diagnosis of Lung Cancer, REHOVOT, ...
(Date:7/21/2008)...lin as consolidation therapy after remission indu...ular lymphoma, SEA...peutics, Inc.,(CTI) (Nasdaq and MTA: CTIC) announc...with the U.S. Food and Drug Administration (FDA) i... supplemental Biologics License,Application (sBLA)...
(Date:7/21/2008)...EAS Study" issued on 21 Jul 2008,07:00 GMT, by Pro... & Head,of Steering Committee over PR Newswire, we...on that the following information has been added t...ccess and URL for webcast:, Satellite: European ...nel 2 DL: 11152.700 V symbol rate 5.632 FEC 3/4...
Breaking Medicine Technology:CeNeRx BioPharma Finalizes Plans to Initiate Phase II Trials for Its Novel Antidepressant Agent Tyrima(TM) Using Innovative Brain Imaging Study 2CeNeRx BioPharma Finalizes Plans to Initiate Phase II Trials for Its Novel Antidepressant Agent Tyrima(TM) Using Innovative Brain Imaging Study 3CeNeRx BioPharma Finalizes Plans to Initiate Phase II Trials for Its Novel Antidepressant Agent Tyrima(TM) Using Innovative Brain Imaging Study 4First Cancer Diagnostic Test Based on Rosetta Genomics' Proprietary MicroRNA Technology Receives Regulatory Approval 2First Cancer Diagnostic Test Based on Rosetta Genomics' Proprietary MicroRNA Technology Receives Regulatory Approval 3First Cancer Diagnostic Test Based on Rosetta Genomics' Proprietary MicroRNA Technology Receives Regulatory Approval 4First Cancer Diagnostic Test Based on Rosetta Genomics' Proprietary MicroRNA Technology Receives Regulatory Approval 5CTI to Meet With the FDA to Discuss Filing of a Supplemental Biologics License Application for Zevalin(R) 2CTI to Meet With the FDA to Discuss Filing of a Supplemental Biologics License Application for Zevalin(R) 3CTI to Meet With the FDA to Discuss Filing of a Supplemental Biologics License Application for Zevalin(R) 4/C O R R E C T I O N -- Prof Terje Pedersen, SEAS Study Principal Investigator & Head of Steering Committee/ 2/C O R R E C T I O N -- Prof Terje Pedersen, SEAS Study Principal Investigator & Head of Steering Committee/ 3WuXi PharmaTech 28NYSE 3A WX 29 Named the Most Innovative Company in China and CEO Dr Li the Most Innovative Leader of Chinese Enterprises 6480 1WuXi PharmaTech 28NYSE 3A WX 29 Named the Most Innovative Company in China and CEO Dr Li the Most Innovative Leader of Chinese Enterprises 6480 2WuXi PharmaTech 28NYSE 3A WX 29 Named the Most Innovative Company in China and CEO Dr Li the Most Innovative Leader of Chinese Enterprises 6480 3WuXi PharmaTech 28NYSE 3A WX 29 Named the Most Innovative Company in China and CEO Dr Li the Most Innovative Leader of Chinese Enterprises 6480 4Pharmaceutical Marketing Done Right 3A Archi Tech Systems Unveils Version of Proven Analytics Solution for Campaign Management 6478 1Pharmaceutical Marketing Done Right 3A Archi Tech Systems Unveils Version of Proven Analytics Solution for Campaign Management 6478 2Insmed Announces First Human Bioequivalence Data for a Follow on Biologic by a U S Company 2614 1Insmed Announces First Human Bioequivalence Data for a Follow on Biologic by a U S Company 2614 2Insmed Announces First Human Bioequivalence Data for a Follow on Biologic by a U S Company 2614 3Insmed Announces First Human Bioequivalence Data for a Follow on Biologic by a U S Company 2614 4Insmed Announces First Human Bioequivalence Data for a Follow on Biologic by a U S Company 2614 5Proteolix Initiates Phase 1b Clinical Trial of Carfilzomib in a Combination Regimen for Patients With Relapsed Multiple Myeloma 2612 1Proteolix Initiates Phase 1b Clinical Trial of Carfilzomib in a Combination Regimen for Patients With Relapsed Multiple Myeloma 2612 2Proteolix Initiates Phase 1b Clinical Trial of Carfilzomib in a Combination Regimen for Patients With Relapsed Multiple Myeloma 2612 3
... -- Additional Findings Reported Safety & Tole...and Healthy Subjects --, CHICAGO, June 25, 2007 /P...his week at the annual meeting of the American Dia...n inhibitor of,dipeptidyl-peptidase-4 (DPP-4) in d...raZeneca , in combination with metformin,exhibite...
... ,Focus On AV411,s Unique Mechanism of Action an...l Conditions , ALAMEDA, Calif., June 26, 2007 (PRI...harmaceutical company innovating therapeutics,for ...d today that,Expert Opinion on Investigational Dru...eline product, AV411 (ibudilast), a potential,firs...
Other Medicine Technology:Data Demonstrated Saxagliptin Added to Metformin Improved Glycemic,Control in Subjects with Type 2 Diabetes Compared to Metformin,Alone 2Data Demonstrated Saxagliptin Added to Metformin Improved Glycemic,Control in Subjects with Type 2 Diabetes Compared to Metformin,Alone 3Data Demonstrated Saxagliptin Added to Metformin Improved Glycemic,Control in Subjects with Type 2 Diabetes Compared to Metformin,Alone 4Data Demonstrated Saxagliptin Added to Metformin Improved Glycemic,Control in Subjects with Type 2 Diabetes Compared to Metformin,Alone 5Data Demonstrated Saxagliptin Added to Metformin Improved Glycemic,Control in Subjects with Type 2 Diabetes Compared to Metformin,Alone 6Expert Opinion Highlights Avigen's AV411 as Potential New,Therapeutic for Neuropathic Pain and Opioid Withdrawal 2Expert Opinion Highlights Avigen's AV411 as Potential New,Therapeutic for Neuropathic Pain and Opioid Withdrawal 3Expert Opinion Highlights Avigen's AV411 as Potential New,Therapeutic for Neuropathic Pain and Opioid Withdrawal 4Expert Opinion Highlights Avigen's AV411 as Potential New,Therapeutic for Neuropathic Pain and Opioid Withdrawal 5
Anti Gliadin IgA Enzyme Immunosay for quantitative determination of Gliadin-IgG antibodies in serum.
...igned as a high throughput primary or backup instr...r offers performance and reliability equal to or g...advanced technology of the AUTION JET AJ-4270 and ...ate results, limiting interference from elevated p...
Assay uses highly specific rabbit anti-estriol antibody reparation - negligible cross-reactivity with other estrogen metabolites. Excellent assay precision and reproducibility. Superior sensitivity
...rone Sulfate (E1S) is the most abundant circulatin... men [1,2]. Estrone Sulfate is a major metabolite ...fe in blood [2,3]. In premenopausal women, estrone...e and estradiol, rising gradually during the folli...
Medicine Products: